Kensey Nash of Exton, PA won the European CE mark of approval to market the firm’s Cartilage Repair Device intended for treatment of articular cartilage defects of the knee.
From the press release:
The Kensey Nash Cartilage Repair Device (CRD) is a biphasic, bioresorbable scaffold intended to be implanted at the site of a focal articular cartilage lesion or osteochondral defect in the knee. The CRD is intended to serve as a scaffold for cellular and matrix in-growth in osteochondral defect repair such as bone and/or cartilage, which is not intrinsic to the stability of the tissue. The product is indicated to support the regeneration of hyaline cartilage and subchondral bone by promoting the correct cellular morphology and structural organization during the healing process.
The Cartilage Repair Device (CRD) is a unique synthetic bioresorbable implant designed to address chondral and osteochondral defects. This CRD technology utilizes a biphasic design that contains two discrete layers, each specifically engineered to favor the growth of the histologically distinct tissues of articular cartilage and subchondral bone. The chondral phase consists of a unique Type I bovine collagen matrix that provides a malleable, flexible substratum that allows cell infiltration and de novo formation of hyaline tissue. The subchondral phase consists of b-TCP (tricalcium phosphate) mineral suspended within a porous bioresorbable synthetic polymer scaffold. This matrix provides an appropriate mechanical and chemical environment to facilitate the influx of cells and remodeling into normal bony architecture, an important component in a successful cartilage regeneration effort..